{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:05:20Z","timestamp":1789067120885,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009854","name":"Duquesne University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.sapharm.2022.12.001","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:04:28Z","timestamp":1670256268000},"page":"599-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-2042","authenticated-orcid":false,"given":"Jordan R.","family":"Covvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M.","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk E.","family":"Evoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.sapharm.2022.12.001_bib1","first-page":"S89","article-title":"Gabapentinoid pharmacology in the context of emerging misuse liability","volume":"61","author":"Evoy","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2022.12.001_bib2","doi-asserted-by":"crossref","first-page":"m1315","DOI":"10.1136\/bmj.m1315","article-title":"Pregabalin and gabapentin for pain","volume":"369","author":"Mathieson","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.sapharm.2022.12.001_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.sapharm.2022.12.001_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.sapharm.2022.12.001_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sapharm.2022.12.001_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.640264","article-title":"Assessment of the safety signal for the abuse potential of pregabalin and gabapentin using the FAERS database and big data search analytics","volume":"12","author":"Papazisis","year":"2021","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sapharm.2022.12.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107926","article-title":"The gabapentinoid drugs and their abuse potential","volume":"227","author":"Goins","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.sapharm.2022.12.001_bib8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s11096-020-01217-8","article-title":"Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample","volume":"43","author":"Evoy","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.sapharm.2022.12.001_bib9","doi-asserted-by":"crossref","DOI":"10.2196\/33919","article-title":"Using named entity recognition to identify substances used in the self-medication of opioid withdrawal: natural language processing study of Reddit data","volume":"6","author":"Preiss","year":"2022","journal-title":"JMIR Form Res"},{"key":"10.1016\/j.sapharm.2022.12.001_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ADM.0b013e3182872718","article-title":"Concerns about pregabalin: further experience with its potential of causing addictive behaviors","volume":"7","author":"Gahr","year":"2013","journal-title":"J Addiction Med"},{"key":"10.1016\/j.sapharm.2022.12.001_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1060028015620800","article-title":"Gabapentin: abuse, dependence, and withdrawal","volume":"50","author":"Mersfelder","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.sapharm.2022.12.001_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000321079","article-title":"Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data","volume":"80","author":"Schifano","year":"2011","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.sapharm.2022.12.001_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","article-title":"Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky","volume":"172","author":"Smith","year":"2015","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.sapharm.2022.12.001_bib14","first-page":"436","article-title":"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population","volume":"38","author":"Peckham","year":"2018","journal-title":"Pharma"},{"key":"10.1016\/j.sapharm.2022.12.001_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-017-0595-1","article-title":"All-cause and drug-related medical events associated with overuse of gabapentin and\/or opioid medications: a retrospective cohort analysis of a commercially insured US population","volume":"41","author":"Peckham","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.sapharm.2022.12.001_bib16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.7326\/M18-1136","article-title":"Pregabalin and the risk for opioid-related death: a nested case-control study","volume":"169","author":"Gomes","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2022.12.001_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.sapharm.2022.12.001_bib18","series-title":"FDA Requires New Warnings for Gabapentinoids about Risk of Respiratory Depression","author":"Food and Drug Administration","year":"2019"},{"issue":"9","key":"10.1016\/j.sapharm.2022.12.001_bib19","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/ajhp\/zxab486","article-title":"State-level response to gabapentin misuse in the United States: implications and future direction","volume":"79","author":"Karavolis","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sapharm.2022.12.001_bib20","author":"gov"},{"key":"10.1016\/j.sapharm.2022.12.001_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13011-020-0256-8","article-title":"The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?","volume":"15","author":"Fischer","year":"2020","journal-title":"Subst Abuse Treat Prev Pol"},{"key":"10.1016\/j.sapharm.2022.12.001_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Healthc Pol"},{"key":"10.1016\/j.sapharm.2022.12.001_bib23","article-title":"Nobody knows how you're supposed to interpret it:\" End-user perspectives on prescription drug monitoring program in Massachusetts","author":"Hong","year":"2021","journal-title":"J Addiction Med"},{"key":"10.1016\/j.sapharm.2022.12.001_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1037\/adb0000337","article-title":"A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky","volume":"32","author":"Vickers Smith","year":"2018","journal-title":"Psychol Addict Behav"},{"issue":"4","key":"10.1016\/j.sapharm.2022.12.001_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G","article-title":"Whatever happened to qualitative description?","volume":"23","author":"Sandelowski","year":"2000","journal-title":"Res Nurs Health"},{"issue":"1","key":"10.1016\/j.sapharm.2022.12.001_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/nur.20362","article-title":"What's in a name? Qualitative description revisited","volume":"33","author":"Sandelowski","year":"2010","journal-title":"Res Nurs Health"},{"key":"10.1016\/j.sapharm.2022.12.001_bib27","series-title":"Qualitative Research and Evaluation Methods: Integrating Theory and Practice","author":"Patton","year":"2014"},{"key":"10.1016\/j.sapharm.2022.12.001_bib28","article-title":"Gabapentin for off-label use: evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst Abuse"},{"issue":"2","key":"10.1016\/j.sapharm.2022.12.001_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.sapharm.2022.12.001_bib30","series-title":"The Coding Manual for Qualitative Researchers","author":"Saldana","year":"2021"},{"issue":"Supplement_2","key":"10.1016\/j.sapharm.2022.12.001_bib32","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1093\/ajhp\/zxy090","article-title":"Impact of hydrocodone reclassification on analgesic prescribing in the Veterans Health Administration","volume":"76","author":"Steckler","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"10.1016\/j.sapharm.2022.12.001_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/pds.4376","article-title":"Decline in opioid prescribing after federal rescheduling of hydrocodone products","volume":"27","author":"Raji","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.sapharm.2022.12.001_bib34","first-page":"532","article-title":"The effect of a federal Controlled Substance Act schedule change on hydrocodone combination products claims in a Medicaid population","volume":"23","author":"Tran","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.sapharm.2022.12.001_bib35","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/10826084.2022.2063898","article-title":"Changes in hydrocodone misuse exposures reported to U.S. poison centers following rescheduling in 2014","volume":"57","author":"Fischer","year":"2022","journal-title":"Subst Use Misuse"},{"issue":"9","key":"10.1016\/j.sapharm.2022.12.001_bib36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/pm\/pnv064","article-title":"An online survey of patients' experiences since the rescheduling of hydrocodone: the first 100 days","volume":"17","author":"Chambers","year":"2016","journal-title":"Pain Med"},{"issue":"4","key":"10.1016\/j.sapharm.2022.12.001_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.36076\/ppj.2018.4.309","article-title":"Reframing the prevention strategies of the opioid crisis: focusing on prescription opioids, fentanyl, and heroin epidemic","volume":"21","author":"Manchikanti","year":"2018","journal-title":"Pain Physician"},{"issue":"2 Suppl","key":"10.1016\/j.sapharm.2022.12.001_bib38","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.7326\/M19-2415","article-title":"Health and Public Policy Committee of the American College of Physicians. Envisioning a better U.S. health care system for all: coverage and cost of care","volume":"172","author":"Crowley","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2022.12.001_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1741-7015-8-8","article-title":"Access to pain treatment as a human right","volume":"8","author":"Lohman","year":"2010","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.sapharm.2022.12.001_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","article-title":"They look at us like junkies\": influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City","volume":"17","author":"Muncan","year":"2020","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.sapharm.2022.12.001_bib44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","article-title":"Stigma at every turn: health services experiences among people who inject drugs","volume":"57","author":"Paquette","year":"2018","journal-title":"Int J Drug Pol"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741122004168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741122004168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:29:26Z","timestamp":1761557366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741122004168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1551741122004168"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2022.12.001","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}